Restem Group Inc.
June 16, 2025
Company Presentation

RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products, robust clinical development expertise, and cutting-edge-manufacturing capabilities, we advance potentially groundbreaking, wholly owned programs, Restem-L, an umbilical cord lining stem cells (ULSCs) for auto-immune diseases, Restem-X, a secretome-based product for orthopedic conditions, and activated natural killer cell (aNK) therapeutics targeting senescence and age-associated disorders. Our therapies are intended to treat a broad range of disabling diseases and are designed to improve patient outcomes, as well as overall health and wellness. RESTEM is headquartered in Miami, Florida.

Company HQ City:
Miami
Company HQ State:
FL
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
Restem-L, an umbilical cord lining stem cell (ULSC) program
CEO
Andres Isaias
Year Founded
2018
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
Interim data read out for our P2/3 clinical trial in immune idiophatic myopathy (IIM)
What is your next catalyst (value inflection) update?
March 2026
Website
www.restem.com
Primary Speaker